These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 33932725)

  • 1. Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells.
    Mout L; van Dessel LF; Kraan J; de Jong AC; Neves RPL; Erkens-Schulze S; Beaufort CM; Sieuwerts AM; van Riet J; Woo TLC; de Wit R; Sleijfer S; Hamberg P; Sandberg Y; Te Boekhorst PAW; van de Werken HJG; Martens JWM; Stoecklein NH; van Weerden WM; Lolkema MP
    Eur J Cancer; 2021 Jun; 150():179-189. PubMed ID: 33932725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukapheresis increases circulating tumour cell yield in non-small cell lung cancer, counts related to tumour response and survival.
    Tamminga M; Andree KC; van den Bos H; Hiltermann TJN; Mentink A; Spierings DCJ; Lansdorp P; Timens W; Schuuring E; Terstappen LWMM; Groen HJM
    Br J Cancer; 2022 Feb; 126(3):409-418. PubMed ID: 34848855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis Products.
    Franken A; Driemel C; Behrens B; Meier-Stiegen F; Endris V; Stenzinger A; Niederacher D; Fischer JC; Stoecklein NH; Ruckhaeberle E; Fehm T; Neubauer H
    Clin Chem; 2019 Apr; 65(4):549-558. PubMed ID: 30737205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells.
    Rieckmann LM; Spohn M; Ruff L; Agorku D; Becker L; Borchers A; Krause J; O'Reilly R; Hille J; Velthaus-Rusik JL; Beumer N; Günther A; Willnow L; Imbusch CD; Iglauer P; Simon R; Franzenburg S; Winter H; Thomas M; Bokemeyer C; Gagliani N; Krebs CF; Sprick M; Hardt O; Riethdorf S; Trumpp A; Stoecklein NH; Peine S; Rosenstiel P; Pantel K; Loges S; Janning M
    Mol Cancer; 2024 May; 23(1):93. PubMed ID: 38720314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting.
    Fehm TN; Meier-Stiegen F; Driemel C; Jäger B; Reinhardt F; Naskou J; Franken A; Neubauer H; Neves RPL; van Dalum G; Ruckhäberle E; Niederacher D; Rox JM; Fischer JC; Stoecklein NH
    Cytometry A; 2018 Dec; 93(12):1213-1219. PubMed ID: 30551262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap).
    Andree KC; Mentink A; Zeune LL; Terstappen LWMM; Stoecklein NH; Neves RP; Driemel C; Lampignano R; Yang L; Neubauer H; Fehm T; Fischer JC; Rossi E; Manicone M; Basso U; Marson P; Zamarchi R; Loriot Y; Lapierre V; Faugeroux V; Oulhen M; Farace F; Fowler G; Sousa Fontes M; Ebbs B; Lambros M; Crespo M; Flohr P; de Bono JS
    Int J Cancer; 2018 Nov; 143(10):2584-2591. PubMed ID: 30006930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis.
    Stoecklein NH; Fluegen G; Guglielmi R; Neves RPL; Hackert T; Birgin E; Cieslik SA; Sudarsanam M; Driemel C; van Dalum G; Franken A; Niederacher D; Neubauer H; Fehm T; Rox JM; Böhme P; Häberle L; Göring W; Esposito I; Topp SA; Coumans FAW; Weitz J; Knoefel WT; Fischer JC; Bork U; Rahbari NN
    Mol Cancer; 2023 Nov; 22(1):181. PubMed ID: 37957606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of size-based separation and selection-free technology provides higher circulating tumour cells detection sensitivity than either method alone in patients with metastatic prostate cancer.
    Dong L; Zhang Z; Smith K; Kuczler MD; Reyes D; Amend SR; Cho YK; Xue W; Pienta KJ
    BJU Int; 2020 Jul; 126(1):191-201. PubMed ID: 32115854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients.
    Fischer JC; Niederacher D; Topp SA; Honisch E; Schumacher S; Schmitz N; Zacarias Föhrding L; Vay C; Hoffmann I; Kasprowicz NS; Hepp PG; Mohrmann S; Nitz U; Stresemann A; Krahn T; Henze T; Griebsch E; Raba K; Rox JM; Wenzel F; Sproll C; Janni W; Fehm T; Klein CA; Knoefel WT; Stoecklein NH
    Proc Natl Acad Sci U S A; 2013 Oct; 110(41):16580-5. PubMed ID: 24065821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved enrichment of circulating tumor cells from diagnostic leukapheresis product.
    Stevens M; Mentink A; Nanou A; Coumans FAW; Isebia KT; Kraan J; Hamberg P; Martens JWM; Terstappen LWMM
    Cytometry A; 2023 Nov; 103(11):881-888. PubMed ID: 37461156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of isolated circulating tumor cells and tissue biopsies using whole-genome sequencing in prostate cancer.
    Jiang R; Lu YT; Ho H; Li B; Chen JF; Lin M; Li F; Wu K; Wu H; Lichterman J; Wan H; Lu CL; OuYang W; Ni M; Wang L; Li G; Lee T; Zhang X; Yang J; Rettig M; Chung LW; Yang H; Li KC; Hou Y; Tseng HR; Hou S; Xu X; Wang J; Posadas EM
    Oncotarget; 2015 Dec; 6(42):44781-93. PubMed ID: 26575023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analogous detection of circulating tumor cells using the AccuCyte
    van der Toom EE; Groot VP; Glavaris SA; Gemenetzis G; Chalfin HJ; Wood LD; Wolfgang CL; de la Rosette JJMCH; de Reijke TM; Pienta KJ
    Prostate; 2018 Mar; 78(4):300-307. PubMed ID: 29285777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Large Number of Circulating Tumor Cells(CTCs)Can Be Isolated from Samples Obtained by Using Leukapheresis Procedures].
    Soya R; Taguchi J; Nagakawa Y; Takahashi O; Sandoh N; Hosokawa Y; Kasuya K; Umeda N; Okamoto M; Tsujitani S; Tsuchida A
    Gan To Kagaku Ryoho; 2015 Sep; 42(9):1069-72. PubMed ID: 26469161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation of rare circulating tumour cells in cancer patients by microchip technology.
    Nagrath S; Sequist LV; Maheswaran S; Bell DW; Irimia D; Ulkus L; Smith MR; Kwak EL; Digumarthy S; Muzikansky A; Ryan P; Balis UJ; Tompkins RG; Haber DA; Toner M
    Nature; 2007 Dec; 450(7173):1235-9. PubMed ID: 18097410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine Resistance.
    Reinhardt F; Franken A; Meier-Stiegen F; Driemel C; Stoecklein NH; Fischer JC; Niederacher D; Ruckhaeberle E; Fehm T; Neubauer H
    Cancers (Basel); 2019 Jun; 11(7):. PubMed ID: 31261643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Technical validation of a new microfluidic device for enrichment of CTCs from large volumes of blood by using buffy coats to mimic diagnostic leukapheresis products.
    Guglielmi R; Lai Z; Raba K; van Dalum G; Wu J; Behrens B; Bhagat AAS; Knoefel WT; Neves RPL; Stoecklein NH
    Sci Rep; 2020 Nov; 10(1):20312. PubMed ID: 33219265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow-based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product.
    Stevens M; Mentink A; Coumans FAW; Dathathri E; Isebia KT; Kraan J; de Wit R; Martens JWM; Terstappen LWMM
    Mol Oncol; 2023 Dec; ():. PubMed ID: 38073130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between drug sensitivity profiles of circulating tumour cell-derived organoids and clinical treatment response in patients with pancreatic ductal adenocarcinoma.
    Wu YH; Hung YP; Chiu NC; Lee RC; Li CP; Chao Y; Shyr YM; Wang SE; Chen SC; Lin SH; Chen YH; Kang YM; Hsu SM; Yen SH; Wu JY; Lee KD; Tseng HE; Tsai JR; Tang JH; Chiou JF; Burnouf T; Chen YJ; Wang PY; Lu LS
    Eur J Cancer; 2022 May; 166():208-218. PubMed ID: 35306319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.